Table 3 Association between serum levels of CRP-bound SAA (CRP-SAA), total SAA and clinical characteristics of the 464 lung cancer patients
From: The prognostic value of serum C-reactive protein-bound serum amyloid A in early-stage lung cancer
Characteristic | CRP-SAA [cases (%)] | P value | Total SAA [cases (%)] | P value | ||
|---|---|---|---|---|---|---|
Low level (OD ≤ 0.10) | High level (OD > 0.10) | Low level (OD ≤ 0.17) | High level (OD > 0.17) | |||
Total | 212 | 252 | Â | 271 | 193 | Â |
Age | Â | Â | 0.725 | Â | Â | 0.741 |
 <60 years | 112 (24.1) | 129 (27.8) |  | 139 (30.0) | 102 (22.0) |  |
 ≥60 years | 100 (21.6) | 123 (26.5) |  | 132 (28.4) | 91 (19.6) |  |
Sex | Â | Â | 0.001 | Â | Â | 0.106 |
 Male | 142 (30.6) | 203 (43.8) |  | 194 (41.8) | 151 (32.5) |  |
 Female | 70 (15.1) | 49 (10.6) |  | 77 (16.6) | 42 (9.1) |  |
Smoking status | Â | Â | <0.001 | Â | Â | <0.001 |
 No | 113 (24.4) | 85 (18.3) |  | 139 (30.0) | 59 (12.7) |  |
 Yes | 99 (21.3) | 167 (36.0) |  | 132 (28.4) | 134 (28.9) |  |
Treatment | Â | Â | <0.001 | Â | Â | <0.001 |
 Multimodality therapy without operation | 86 (18.5) | 54 (11.6) |  | 112 (24.1) | 28 (6.0) |  |
 Operation alone | 62 (13.4) | 76 (16.4) |  | 82 (17.7) | 56 (12.1) |  |
 Operation and multimodality therapy | 64 (13.8) | 122 (26.3) |  | 77 (16.6) | 109 (23.5) |  |
T stage | Â | Â | <0.001 | Â | Â | <0.001 |
 T1 | 41 (8.8) | 29 (6.3) |  | 54 (11.6) | 16 (3.4) |  |
 T2 | 109 (23.5) | 100 (21.6) |  | 130 (28.0) | 79 (17.0) |  |
 T3 | 32 (6.9) | 82 (17.7) |  | 51 (11.0) | 63 (13.6) |  |
 T4 | 30 (6.5) | 41 (8.8) |  | 36 (7.8) | 35 (7.5) |  |
N stage | Â | Â | <0.001 | Â | Â | <0.001 |
 N0 | 93 (20.0) | 72 (15.5) |  | 113 (24.4) | 52 (11.2) |  |
 N1 | 33 (7.1) | 41 (8.8) |  | 47 (10.1) | 27 (5.8) |  |
 N2 | 68 (14.7) | 90 (19.4) |  | 84 (18.1) | 74 (15.9) |  |
 N3 | 18 (3.9) | 49 (10.6) |  | 27 (5.8) | 40 (8.6) |  |
M stage | Â | Â | <0.001 | Â | Â | <0.001 |
 M0 | 174 (37.5) | 155 (33.4) |  | 213 (45.9) | 116 (25.0) |  |
 M1 | 38 (8.2) | 97 (20.9) |  | 58 (12.5) | 77 (16.6) |  |
Clinical stage | Â | Â | <0.001 | Â | Â | <0.001 |
 I | 57 (12.3) | 19 (4.1) |  | 61 (13.1) | 15 (3.2) |  |
 II | 41 (8.8) | 42 (9.1) |  | 60 (12.9) | 23 (5.0) |  |
 III | 76 (16.4) | 94 (20.3) |  | 92 (19.8) | 78 (16.8) |  |
 IV | 38 (8.2) | 97 (20.9) |  | 58 (12.5) | 77 (16.6) |  |
Pathologic type | Â | Â | 0.192 | Â | Â | 0.784 |
 Adenocarcinoma | 112 (24.1) | 131 (28.2) |  | 147(31.7) | 96(20.7) |  |
 Squamous cell carcinoma | 65 (14.0) | 65 (14.0) |  | 72 (15.5) | 58 (12.5) |  |
 Small cell carcinoma | 15 (3.2) | 33 (7.1) |  | 26 (5.6) | 22 (4.7) |  |
 Others | 20 (4.3) | 23 (5.0) |  | 26 (5.6) | 17 (3.7) |  |
Primary tumor site | Â | Â | 0.821 | Â | Â | 0.301 |
 Left lung | 86 (18.5) | 107 (23.1) |  | 105 (22.6) | 88 (19.0) |  |
 Right lung | 126 (27.2) | 145 (31.3) |  | 166 (35.8) | 105 (22.6) |  |